TOXICOLOGY DATA MANAGEMENT SYSTEM HISTORICAL CONTROL TUMOR INCIDENCE SUMMARY =========================================================================== ALL ORGANS B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Benign Tumors Total 22/50(44%) 34/50(68%) Mean(sd) Range 22/50 - 22/50 34/50 - 34/50 Males 22/50 Females 34/50 --------------------------------------------------------------------------- Malignant Tumors Total 32/50(64%) 35/50(70%) Mean(sd) Range 32/50 - 32/50 35/50 - 35/50 Males 32/50 Females 35/50 --------------------------------------------------------------------------- Malignant and Benign Total 42/50(84%) 48/50(96%) Tumors Mean(sd) Range 42/50 - 42/50 48/50 - 48/50 Males 42/50 Females 48/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) 1/50(2%) Mean(sd) Range 0/50 - 0/50 1/50 - 1/50 Males 0/50 Females 1/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 4/50(8%) 2/50(4%) Mean(sd) Range 4/50 - 4/50 2/50 - 2/50 Males 4/50 Females 2/50 --------------------------------------------------------------------------- Hemangiosarcoma or Total 4/50(8%) 3/50(6%) Hemangioma Mean(sd) Range 4/50 - 4/50 3/50 - 3/50 Males 4/50 Females 3/50 --------------------------------------------------------------------------- Histiocytic Sarcoma Total 0/50(0%) 2/50(4%) Mean(sd) Range 0/50 - 0/50 2/50 - 2/50 Males 0/50 Females 2/50 --------------------------------------------------------------------------- Leukemia: Erythrocytic Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Leukemia: Granulocytic Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Leukemia: Lymphocytic, Total 0/50(0%) 0/50(0%) Monocytic, Mononuclear, Mean(sd) or Undifferentiated Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Malignant Lymphoma: Total 4/50(8%) 11/50(22%) Histiocytic, Mean(sd) Lymphocytic, Mixed, NOS, Range 4/50 - 4/50 11/50 - 11/50 or Undifferentiated Cell Type Males 4/50 Females 11/50 --------------------------------------------------------------------------- Osteoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Osteosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Osteosarcoma or Osteoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== ADRENAL CORTEX B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 1/50(2%) 1/50(2%) Mean(sd) Range 1/50 - 1/50 1/50 - 1/50 Males 1/50 Females 1/50 --------------------------------------------------------------------------- Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Plasma Cell Tumor Total 0/50(0%) 0/50(0%) Malignant Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== ADRENAL GLAND: NON-MEDULLARY, NON-CORTICAL B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== ADRENAL MEDULLA B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Pheochromocytoma Benign Total 1/49(2%) 0/50(0%) Mean(sd) Range 1/49 - 1/49 0/50 - 0/50 Males 1/49 Females 0/50 --------------------------------------------------------------------------- Pheochromocytoma Complex Total 0/49(0%) 0/50(0%) Mean(sd) Range 0/49 - 0/49 0/50 - 0/50 Males 0/49 Females 0/50 --------------------------------------------------------------------------- Pheochromocytoma Total 0/49(0%) 1/50(2%) Malignant Mean(sd) Range 0/49 - 0/49 1/50 - 1/50 Males 0/49 Females 1/50 --------------------------------------------------------------------------- Pheochromocytoma: Total 1/49(2%) 1/50(2%) Benign, Complex, Mean(sd) Malignant, NOS Range 1/49 - 1/49 1/50 - 1/50 Males 1/49 Females 1/50 --------------------------------------------------------------------------- =========================================================================== BONE MARROW B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrous Histiocytoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Mast Cell Tumor Total 0/50(0%) 0/50(0%) Malignant Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Mast Cell Tumor NOS Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Plasma Cell Tumor Total 0/50(0%) 0/50(0%) Malignant Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== BONE B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Osteoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Osteosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Osteosarcoma or Osteoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== BRAIN B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Astrocytoma Benign Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Meningioma Malignant Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Meningioma: Benign, Total 0/50(0%) 0/50(0%) Malignant, NOS Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Oligodendroglioma Benign Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Oligodendroglioma Total 0/50(0%) 0/50(0%) Malignant Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Oligodendroglioma, Total 0/50(0%) 0/50(0%) Glioma, or Astrocytoma Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== CLITORAL/PREPUTIAL GLAND B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== EAR B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Basosquamous Tumor Total 0/50(0%) 0/50(0%) Malignant Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Fibroma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Fibrosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== EPIDIDYMIS B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrous Histiocytoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Males 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Males 0/50 --------------------------------------------------------------------------- Leiomyoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Males 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Males 0/50 --------------------------------------------------------------------------- =========================================================================== ESOPHAGUS B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== EYE B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== GALLBLADDER B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/45(0%) 0/45(0%) Mean(sd) Range 0/45 - 0/45 0/45 - 0/45 Males 0/45 Females 0/45 --------------------------------------------------------------------------- =========================================================================== HARDERIAN GLAND B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 2/50(4%) 2/50(4%) Mean(sd) Range 2/50 - 2/50 2/50 - 2/50 Males 2/50 Females 2/50 --------------------------------------------------------------------------- Carcinoma Total 2/50(4%) 1/50(2%) Mean(sd) Range 2/50 - 2/50 1/50 - 1/50 Males 2/50 Females 1/50 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 4/50(8%) 3/50(6%) Mean(sd) Range 4/50 - 4/50 3/50 - 3/50 Males 4/50 Females 3/50 --------------------------------------------------------------------------- =========================================================================== HEART B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrous Histiocytoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== INTESTINE LARGE: CECUM B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Fibrosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Leiomyoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== INTESTINE LARGE: COLON/RECTUM B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrous Histiocytoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Leiomyosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Papilloma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== INTESTINE SMALL: DUODENUM B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Leiomyosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Polyp Adenomatous Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== INTESTINE SMALL: ILEUM B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== INTESTINE SMALL: JEJUNUM B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma Total 1/50(2%) 0/50(0%) Mean(sd) Range 1/50 - 1/50 0/50 - 0/50 Males 1/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Leiomyosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Polyp Adenomatous Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== INTESTINE SMALL: SITE UNSPECIFIED B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma Total 1/50(2%) 0/50(0%) Mean(sd) Range 1/50 - 1/50 0/50 - 0/50 Males 1/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 1/50(2%) 0/50(0%) Mean(sd) Range 1/50 - 1/50 0/50 - 0/50 Males 1/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Leiomyosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Polyp Adenomatous Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== ISLETS, PANCREATIC B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) 0/48(0%) Mean(sd) Range 0/50 - 0/50 0/48 - 0/48 Males 0/50 Females 0/48 --------------------------------------------------------------------------- Carcinoma Total 0/50(0%) 0/48(0%) Mean(sd) Range 0/50 - 0/50 0/48 - 0/48 Males 0/50 Females 0/48 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 0/50(0%) 0/48(0%) Mean(sd) Range 0/50 - 0/50 0/48 - 0/48 Males 0/50 Females 0/48 --------------------------------------------------------------------------- =========================================================================== KIDNEY: PELVIS AND TRANSITIONAL EPITHELIUM B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Carcinoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Hemangioma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- =========================================================================== KIDNEY: RENAL TUBULE B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Carcinoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Fibrous Histiocytoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Sarcoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- =========================================================================== LIVER B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Cholangiocarcinoma Total 0/50(0%) 0/49(0%) Mean(sd) Range 0/50 - 0/50 0/49 - 0/49 Males 0/50 Females 0/49 --------------------------------------------------------------------------- Cholangioma Total 0/50(0%) 0/49(0%) Mean(sd) Range 0/50 - 0/50 0/49 - 0/49 Males 0/50 Females 0/49 --------------------------------------------------------------------------- Fibrous Histiocytoma Total 0/50(0%) 0/49(0%) Mean(sd) Range 0/50 - 0/50 0/49 - 0/49 Males 0/50 Females 0/49 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) 1/49(2%) Mean(sd) Range 0/50 - 0/50 1/49 - 1/49 Males 0/50 Females 1/49 --------------------------------------------------------------------------- Hemangiosarcoma Total 4/50(8%) 0/49(0%) Mean(sd) Range 4/50 - 4/50 0/49 - 0/49 Males 4/50 Females 0/49 --------------------------------------------------------------------------- Hepatoblastoma Total 2/50(4%) 0/49(0%) Mean(sd) Range 2/50 - 2/50 0/49 - 0/49 Males 2/50 Females 0/49 --------------------------------------------------------------------------- Hepatocellular Adenoma Total 14/50(28%) 24/49(49%) Mean(sd) Range 14/50 - 14/50 24/49 - 24/49 Males 14/50 Females 24/49 --------------------------------------------------------------------------- Hepatocellular Carcinoma Total 18/50(36%) 16/49(32.7%) Mean(sd) Range 18/50 - 18/50 16/49 - 16/49 Males 18/50 Females 16/49 --------------------------------------------------------------------------- Hepatocellular Total 20/50(40%) 16/49(32.7%) Carcinoma or Mean(sd) Hepatoblastoma Range 20/50 - 20/50 16/49 - 16/49 Males 20/50 Females 16/49 --------------------------------------------------------------------------- Hepatocellular Total 28/50(56%) 33/49(67.3%) Carcinoma or Mean(sd) Hepatocellular Adenoma Range 28/50 - 28/50 33/49 - 33/49 Males 28/50 Females 33/49 --------------------------------------------------------------------------- Hepatocellular Total 30/50(60%) 33/49(67.3%) Carcinoma, Mean(sd) Hepatocellular Adenoma, Range 30/50 - 30/50 33/49 - 33/49 or Hepatoblastoma Males 30/50 Females 33/49 --------------------------------------------------------------------------- Hepatocholangiocarcinoma Total 1/50(2%) 1/49(2%) Mean(sd) Range 1/50 - 1/50 1/49 - 1/49 Males 1/50 Females 1/49 --------------------------------------------------------------------------- Ito Cell Tumor Benign Total 0/50(0%) 0/49(0%) Mean(sd) Range 0/50 - 0/50 0/49 - 0/49 Males 0/50 Females 0/49 --------------------------------------------------------------------------- Ito Cell Tumor Malignant Total 0/50(0%) 0/49(0%) Mean(sd) Range 0/50 - 0/50 0/49 - 0/49 Males 0/50 Females 0/49 --------------------------------------------------------------------------- Ito Cell Tumor NOS Total 0/50(0%) 0/49(0%) Mean(sd) Range 0/50 - 0/50 0/49 - 0/49 Males 0/50 Females 0/49 --------------------------------------------------------------------------- Mast Cell Tumor Total 0/50(0%) 0/49(0%) Malignant Mean(sd) Range 0/50 - 0/50 0/49 - 0/49 Males 0/50 Females 0/49 --------------------------------------------------------------------------- Plasma Cell Tumor Total 0/50(0%) 0/49(0%) Malignant Mean(sd) Range 0/50 - 0/50 0/49 - 0/49 Males 0/50 Females 0/49 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/49(0%) Mean(sd) Range 0/50 - 0/50 0/49 - 0/49 Males 0/50 Females 0/49 --------------------------------------------------------------------------- =========================================================================== LUNG B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Alveolar/Bronchiolar Total 9/50(18%) 0/50(0%) Adenoma Mean(sd) Range 9/50 - 9/50 0/50 - 0/50 Males 9/50 Females 0/50 --------------------------------------------------------------------------- Alveolar/Bronchiolar Total 5/50(10%) 2/50(4%) Carcinoma Mean(sd) Range 5/50 - 5/50 2/50 - 2/50 Males 5/50 Females 2/50 --------------------------------------------------------------------------- Alveolar/Bronchiolar Total 13/50(26%) 2/50(4%) Carcinoma or Mean(sd) Alveolar/Bronchiolar Range 13/50 - 13/50 2/50 - 2/50 Adenoma Males 13/50 Females 2/50 --------------------------------------------------------------------------- Fibrous Histiocytoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Mast Cell Tumor Total 0/50(0%) 0/50(0%) Malignant Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== LYMPH NODE, MANDIBULAR B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrous Histiocytoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== LYMPH NODE, MESENTERIC B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrous Histiocytoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Plasma Cell Tumor Total 0/50(0%) 0/50(0%) Malignant Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== LYMPH NODE B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrous Histiocytoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Liposarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Plasma Cell Tumor Total 0/50(0%) 0/50(0%) Malignant Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== LYMPH NODE: MESENTERIC B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrous Histiocytoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== MAMMARY GLAND B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Fibroma, Fibroadenoma Total 0/50(0%) 0/50(0%) or Adenoma Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Fibroma, Fibroadenoma, Total 0/50(0%) 0/50(0%) Carcinoma, or Adenoma Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Myoepithelioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== MESENTERY B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Chemodectoma Malignant Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Fibroma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Fibrosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Fibrous Histiocytoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Lipoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Liposarcoma Total 0/50(0%) 1/50(2%) Mean(sd) Range 0/50 - 0/50 1/50 - 1/50 Males 0/50 Females 1/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== NOSE B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== ORAL CAVITY (ORAL MUCOSA, TONGUE, PHARYNX, TOOTH, GINGIVA) B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Papilloma Squamous or Total 0/50(0%) 0/50(0%) Papilloma Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Total 0/50(0%) 0/50(0%) Carcinoma, Papilloma Mean(sd) Squamous, or Papilloma Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== ORAL MUCOSA B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Squamous Cell Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== OVARY B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Arrhenoblastoma Benign Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Arrhenoblastoma NOS Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Carcinoma Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Cystadenoma Total 4/46(8.7%) Mean(sd) Range 4/46 - 4/46 Females 4/46 --------------------------------------------------------------------------- Fibrous Histiocytoma Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Granulosa Cell Tumor Total 1/46(2.2%) Benign Mean(sd) Range 1/46 - 1/46 Females 1/46 --------------------------------------------------------------------------- Granulosa Cell Tumor Total 0/46(0%) Malignant Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Granulosa Cell Tumor: Total 1/46(2.2%) Benign, Malignant, NOS Mean(sd) Range 1/46 - 1/46 Females 1/46 --------------------------------------------------------------------------- Granulosa-Theca Tumor Total 0/46(0%) Malignant Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Hemangioma Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Liposarcoma Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Luteoma Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Teratoma Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Teratoma Benign Total 1/46(2.2%) Mean(sd) Range 1/46 - 1/46 Females 1/46 --------------------------------------------------------------------------- Teratoma Malignant Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Teratoma NOS Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Thecoma Benign Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Tubulostromal Adenoma Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- Yolk Sac Carcinoma Total 0/46(0%) Mean(sd) Range 0/46 - 0/46 Females 0/46 --------------------------------------------------------------------------- =========================================================================== PANCREAS B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/49(0%) 1/48(2.1%) Mean(sd) Range 0/49 - 0/49 1/48 - 1/48 Males 0/49 Females 1/48 --------------------------------------------------------------------------- Carcinoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 0/49(0%) 1/48(2.1%) Mean(sd) Range 0/49 - 0/49 1/48 - 1/48 Males 0/49 Females 1/48 --------------------------------------------------------------------------- Fibrosarcoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Fibrous Histiocytoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Hemangioma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- Sarcoma Total 0/49(0%) 0/48(0%) Mean(sd) Range 0/49 - 0/49 0/48 - 0/48 Males 0/49 Females 0/48 --------------------------------------------------------------------------- =========================================================================== PARATHYROID GLAND B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Carcinoma Total 0/49(0%) 0/44(0%) Mean(sd) Range 0/49 - 0/49 0/44 - 0/44 Males 0/49 Females 0/44 --------------------------------------------------------------------------- =========================================================================== PHARYNX B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Squamous Cell Papilloma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== PITUITARY GLAND: PARS DISTALIS OR UNSPECIFIED SITE B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/45(0%) 11/46(23.9%) Mean(sd) Range 0/45 - 0/45 11/46 - 11/46 Males 0/45 Females 11/46 --------------------------------------------------------------------------- Carcinoma Total 0/45(0%) 0/46(0%) Mean(sd) Range 0/45 - 0/45 0/46 - 0/46 Males 0/45 Females 0/46 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 0/45(0%) 11/46(23.9%) Mean(sd) Range 0/45 - 0/45 11/46 - 11/46 Males 0/45 Females 11/46 --------------------------------------------------------------------------- =========================================================================== PITUITARY GLAND: PARS INTERMEDIA B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/45(0%) 0/46(0%) Mean(sd) Range 0/45 - 0/45 0/46 - 0/46 Males 0/45 Females 0/46 --------------------------------------------------------------------------- Carcinoma Total 0/45(0%) 0/46(0%) Mean(sd) Range 0/45 - 0/45 0/46 - 0/46 Males 0/45 Females 0/46 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 0/45(0%) 0/46(0%) Mean(sd) Range 0/45 - 0/45 0/46 - 0/46 Males 0/45 Females 0/46 --------------------------------------------------------------------------- =========================================================================== PROSTATE B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Carcinoma Total 0/49(0%) Mean(sd) Range 0/49 - 0/49 Males 0/49 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 0/49(0%) Mean(sd) Range 0/49 - 0/49 Males 0/49 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/49(0%) Mean(sd) Range 0/49 - 0/49 Males 0/49 --------------------------------------------------------------------------- =========================================================================== SALIVARY GLANDS B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Hemangioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== SEMINAL VESICLE B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Males 0/50 --------------------------------------------------------------------------- Carcinoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Males 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Males 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Males 0/50 --------------------------------------------------------------------------- =========================================================================== SKELETAL MUSCLE B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Osteosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Rhabdomyosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Rhabdomyosarcoma or Total 0/50(0%) 0/50(0%) Rhabdomyoma Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== SKIN1: SEBACEOUS GLAND B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== SKIN2 B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Basal Cell Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Basal Cell Adenoma or Total 0/50(0%) 0/50(0%) Basosquamous Tumor Mean(sd) Benign Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Basal Cell Adenoma, Total 0/50(0%) 0/50(0%) Basosquamous Tumor Mean(sd) Benign, or Range 0/50 - 0/50 0/50 - 0/50 Trichoepithelioma Males 0/50 Females 0/50 --------------------------------------------------------------------------- Basal Cell Carcinoma Total 0/50(0%) 1/50(2%) Mean(sd) Range 0/50 - 0/50 1/50 - 1/50 Males 0/50 Females 1/50 --------------------------------------------------------------------------- Basal Cell Carcinoma Total 0/50(0%) 1/50(2%) or Basosquamous Tumor Mean(sd) (malignant or NOS) Range 0/50 - 0/50 1/50 - 1/50 Males 0/50 Females 1/50 --------------------------------------------------------------------------- Basal Cell Carcinoma, Total 0/50(0%) 1/50(2%) Basal Cell Adenoma, Mean(sd) Basosquamous Tumor Range 0/50 - 0/50 1/50 - 1/50 (benign, malignant or NOS), or Trichoepithelioma Males 0/50 Females 1/50 --------------------------------------------------------------------------- Basal or Sq. Cell Total 0/50(0%) 2/50(4%) Carcinoma, Carcinoma, Mean(sd) Basosq. Tumor (M or B), Range 0/50 - 0/50 2/50 - 2/50 Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepithelioma Males 0/50 Females 2/50 --------------------------------------------------------------------------- Basosquamous Tumor Total 0/50(0%) 0/50(0%) Benign Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Basosquamous Tumor Total 0/50(0%) 0/50(0%) Malignant Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 2/50(4%) Mean(sd) Range 0/50 - 0/50 2/50 - 2/50 Males 0/50 Females 2/50 --------------------------------------------------------------------------- Keratoacanthoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Leiomyosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Lipoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Mast Cell Tumor Total 0/50(0%) 0/50(0%) Malignant Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Melanoma Benign Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Osteosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Paraganglioma Benign Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Total 0/50(0%) 1/50(2%) Carcinoma, Basal Cell Mean(sd) Carcinoma, Basosquamous Range 0/50 - 0/50 1/50 - 1/50 Tumor (malignant or NOS), or Carcinoma Males 0/50 Females 1/50 --------------------------------------------------------------------------- Squamous Cell Papilloma Total 0/50(0%) 1/50(2%) Mean(sd) Range 0/50 - 0/50 1/50 - 1/50 Males 0/50 Females 1/50 --------------------------------------------------------------------------- Squamous Cell Total 0/50(0%) 1/50(2%) Papilloma or Papilloma Mean(sd) Range 0/50 - 0/50 1/50 - 1/50 Males 0/50 Females 1/50 --------------------------------------------------------------------------- Squamous Cell Total 0/50(0%) 1/50(2%) Papilloma, Papilloma, Mean(sd) Squamous Cell Carcinoma Range 0/50 - 0/50 1/50 - 1/50 or Keratoacanthoma Males 0/50 Females 1/50 --------------------------------------------------------------------------- Squamous Cell Total 0/50(0%) 1/50(2%) Papilloma, Papilloma, or Mean(sd) Keratoacanthoma Range 0/50 - 0/50 1/50 - 1/50 Males 0/50 Females 1/50 --------------------------------------------------------------------------- Trichoepithelioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== SKIN3 B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibroma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Fibroma, Fibrosarcoma, Total 0/50(0%) 2/50(4%) Sarcoma, Myxoma, Mean(sd) Myxosarcoma, or Fibrous Range 0/50 - 0/50 2/50 - 2/50 Histiocytoma Males 0/50 Females 2/50 --------------------------------------------------------------------------- Fibrosarcoma Total 0/50(0%) 2/50(4%) Mean(sd) Range 0/50 - 0/50 2/50 - 2/50 Males 0/50 Females 2/50 --------------------------------------------------------------------------- Fibrosarcoma, Sarcoma, Total 0/50(0%) 2/50(4%) Myxosarcoma, or Fibrous Mean(sd) Histiocytoma Range 0/50 - 0/50 2/50 - 2/50 Males 0/50 Females 2/50 --------------------------------------------------------------------------- Fibrous Histiocytoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Myxosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Neurofibrosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Neurofibrosarcoma or Total 0/50(0%) 0/50(0%) Schwannoma (malignant or Mean(sd) NOS) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Neurofibrosarcoma, Total 0/50(0%) 0/50(0%) Neurofibroma, or Mean(sd) Schwannoma (benign, Range 0/50 - 0/50 0/50 - 0/50 malignant or NOS) Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Schwannoma Malignant Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== SPINAL CORD B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Schwannoma Malignant Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== SPLEEN B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrosarcoma Total 0/49(0%) 0/47(0%) Mean(sd) Range 0/49 - 0/49 0/47 - 0/47 Males 0/49 Females 0/47 --------------------------------------------------------------------------- Fibrous Histiocytoma Total 0/49(0%) 0/47(0%) Mean(sd) Range 0/49 - 0/49 0/47 - 0/47 Males 0/49 Females 0/47 --------------------------------------------------------------------------- Hemangioma Total 0/49(0%) 0/47(0%) Mean(sd) Range 0/49 - 0/49 0/47 - 0/47 Males 0/49 Females 0/47 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/49(0%) 1/47(2.1%) Mean(sd) Range 0/49 - 0/49 1/47 - 1/47 Males 0/49 Females 1/47 --------------------------------------------------------------------------- Mast Cell Tumor Total 0/49(0%) 0/47(0%) Malignant Mean(sd) Range 0/49 - 0/49 0/47 - 0/47 Males 0/49 Females 0/47 --------------------------------------------------------------------------- Plasma Cell Tumor Total 0/49(0%) 0/47(0%) Malignant Mean(sd) Range 0/49 - 0/49 0/47 - 0/47 Males 0/49 Females 0/47 --------------------------------------------------------------------------- =========================================================================== STOMACH, FORESTOMACH B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Hemangioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Leiomyoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Mast Cell Tumor Benign Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Total 0/50(0%) 0/50(0%) Carcinoma or Papilloma Mean(sd) Squamous Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Papilloma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== STOMACH, GLANDULAR B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 1/50(2%) 0/50(0%) Mean(sd) Range 1/50 - 1/50 0/50 - 0/50 Males 1/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 1/50(2%) 0/50(0%) Mean(sd) Range 1/50 - 1/50 0/50 - 0/50 Males 1/50 Females 0/50 --------------------------------------------------------------------------- Fibrosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== TESTES B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Males 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Males 0/50 --------------------------------------------------------------------------- =========================================================================== THYMUS B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrosarcoma Total 0/38(0%) 0/41(0%) Mean(sd) Range 0/38 - 0/38 0/41 - 0/41 Males 0/38 Females 0/41 --------------------------------------------------------------------------- Fibrous Histiocytoma Total 0/38(0%) 0/41(0%) Mean(sd) Range 0/38 - 0/38 0/41 - 0/41 Males 0/38 Females 0/41 --------------------------------------------------------------------------- Hemangioma Total 0/38(0%) 0/41(0%) Mean(sd) Range 0/38 - 0/38 0/41 - 0/41 Males 0/38 Females 0/41 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/38(0%) 0/41(0%) Mean(sd) Range 0/38 - 0/38 0/41 - 0/41 Males 0/38 Females 0/41 --------------------------------------------------------------------------- Mast Cell Tumor Total 0/38(0%) 0/41(0%) Malignant Mean(sd) Range 0/38 - 0/38 0/41 - 0/41 Males 0/38 Females 0/41 --------------------------------------------------------------------------- Sarcoma Total 0/38(0%) 0/41(0%) Mean(sd) Range 0/38 - 0/38 0/41 - 0/41 Males 0/38 Females 0/41 --------------------------------------------------------------------------- Thymoma Benign Total 0/38(0%) 0/41(0%) Mean(sd) Range 0/38 - 0/38 0/41 - 0/41 Males 0/38 Females 0/41 --------------------------------------------------------------------------- Thymoma Malignant Total 0/38(0%) 0/41(0%) Mean(sd) Range 0/38 - 0/38 0/41 - 0/41 Males 0/38 Females 0/41 --------------------------------------------------------------------------- Thymoma NOS Total 0/38(0%) 0/41(0%) Mean(sd) Range 0/38 - 0/38 0/41 - 0/41 Males 0/38 Females 0/41 --------------------------------------------------------------------------- Thymoma: Benign, Total 0/38(0%) 0/41(0%) Malignant, NOS Mean(sd) Range 0/38 - 0/38 0/41 - 0/41 Males 0/38 Females 0/41 --------------------------------------------------------------------------- =========================================================================== THYROID GLAND: C-CELL B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== THYROID GLAND: FOLLICULAR CELL B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 1/50(2%) 5/50(10%) Mean(sd) Range 1/50 - 1/50 5/50 - 5/50 Males 1/50 Females 5/50 --------------------------------------------------------------------------- Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 1/50(2%) 5/50(10%) Mean(sd) Range 1/50 - 1/50 5/50 - 5/50 Males 1/50 Females 5/50 --------------------------------------------------------------------------- =========================================================================== TISSUE NOS B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Fibrosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Leiomyoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Leiomyosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Lipoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Rhabdomyosarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== TONGUE B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Squamous Cell Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Total 0/50(0%) 0/50(0%) Carcinoma or Papilloma Mean(sd) Squamous Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Papilloma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== TOOTH B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adamantinoma Benign Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Odontoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== URINARY BLADDER B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Carcinoma or Papilloma Total 0/49(0%) 0/50(0%) Mean(sd) Range 0/49 - 0/49 0/50 - 0/50 Males 0/49 Females 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/49(0%) 0/50(0%) Mean(sd) Range 0/49 - 0/49 0/50 - 0/50 Males 0/49 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/49(0%) 0/50(0%) Mean(sd) Range 0/49 - 0/49 0/50 - 0/50 Males 0/49 Females 0/50 --------------------------------------------------------------------------- Leiomyosarcoma Total 0/49(0%) 0/50(0%) Mean(sd) Range 0/49 - 0/49 0/50 - 0/50 Males 0/49 Females 0/50 --------------------------------------------------------------------------- Papilloma Total 0/49(0%) 0/50(0%) Mean(sd) Range 0/49 - 0/49 0/50 - 0/50 Males 0/49 Females 0/50 --------------------------------------------------------------------------- =========================================================================== UTERUS B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Females 0/50 --------------------------------------------------------------------------- Deciduoma Benign Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Females 0/50 --------------------------------------------------------------------------- Granular Cell Tumor Total 0/50(0%) Benign Mean(sd) Range 0/50 - 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangioma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Females 0/50 --------------------------------------------------------------------------- Hemangiosarcoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Females 0/50 --------------------------------------------------------------------------- Leiomyoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Females 0/50 --------------------------------------------------------------------------- Leiomyosarcoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Females 0/50 --------------------------------------------------------------------------- Polyp Stromal Total 1/50(2%) Mean(sd) Range 1/50 - 1/50 Females 1/50 --------------------------------------------------------------------------- Sarcoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Females 0/50 --------------------------------------------------------------------------- Sarcoma Stromal Total 1/50(2%) Mean(sd) Range 1/50 - 1/50 Females 1/50 --------------------------------------------------------------------------- Sarcoma Stromal or Total 2/50(4%) Polyp Stromal Mean(sd) Range 2/50 - 2/50 Females 2/50 --------------------------------------------------------------------------- =========================================================================== VAGINA B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Leiomyosarcoma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Females 0/50 --------------------------------------------------------------------------- Squamous Cell Carcinoma Total 1/50(2%) Mean(sd) Range 1/50 - 1/50 Females 1/50 --------------------------------------------------------------------------- Squamous Cell Papilloma Total 0/50(0%) Mean(sd) Range 0/50 - 0/50 Females 0/50 --------------------------------------------------------------------------- =========================================================================== ZYMBAL'S GLAND B6C3F1 MICE SUBCUTANEOUS BUFFERED SERUM (Updated 12/99) Males(1 study) Females(1 study) =========================================================================== Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 --------------------------------------------------------------------------- Carcinoma or Adenoma Total 0/50(0%) 0/50(0%) Mean(sd) Range 0/50 - 0/50 0/50 - 0/50 Males 0/50 Females 0/50 ---------------------------------------------------------------------------